Quote this publication Share Print

SIFROL

-
Opinions on drugs - Posted on May 21 2013

Reason for request

Re-assessment of the Actual Benefit and Improvement in Actual Benefit for the symptomatic treatment of idiopathic restless legs syndrome (RLS at the request of the Committee (pursuant to article R 163-21 of the French Social Security Code).

-


Actual benefit

Modéré

Moderate in patients with very severe idiopathic RLS.


Improvement in actual benefit

IV (mineur)

SIFROL provides a minor improvement in actual benefit (IAB IV) in the management of patients with very severe idiopathic restless legs syndrome.


Contact Us

Évaluation des médicaments

See also